Clinical Research Directory
Browse clinical research sites, groups, and studies.
Early Postoperative Triple Targeted Therapy in Patients With CHD-PAH in the "Grey Zone"
Sponsor: China National Center for Cardiovascular Diseases
Summary
The purpose of this study is to observe the efficacy of early application of triple targeted drug therapy, including trilostane, in patients with congenital heart disease who are in the "gray zone" of preoperative evaluation, have surgical repair indications after evaluation, and have undergone defect repair.
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2022-08-25
Completion Date
2025-08-31
Last Updated
2026-09-28
Healthy Volunteers
No
Interventions
Control group (ambrisentan plus tadalafil or macitentan plus tadalafil)
The control group received dual drug therapy: endothelin receptor antagonists (Ambrisentan 10mg qd, or Macitentan 10mg qd) combined with phosphodiesterase type 5 inhibitors (Tadalafil 20-40mg qd).
Treatment group (ambrisentan plus tadalafil plus treprostinil or macitentan plus tadalafil plus treprostinil)
The treatment group received early triple therapy: endothelin receptor antagonist (Ambrisentan 10 mg qd or Macitentan 10 mg qd), a phosphodiesterase type 5 inhibitor ( Tadalafil 20-40 mg qd), and treprostinil. The Treprostinil dose was titrated gradually, starting at 1.25 ng/min/kg and escalated to the patient's maximum tolerated dose (target dose range: 15-20 ng/min/kg).
Locations (1)
Fuwai Hospital, National Center for Cardiovascular Diseases
Beijing, China